Dysregulated miRNAs in a canine model of haemangiosarcoma metastatic to the brain.
PTEN
brain metastases
dog
haemangiosarcoma
miRNA
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
revised:
11
11
2023
received:
19
06
2023
accepted:
01
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Haemangiosarcoma is a highly metastatic and lethal cancer of blood vessel-forming cells that commonly spreads to the brain in both humans and dogs. Dysregulations in phosphatase and tensin (PTEN) homologue have been identified in various types of cancers, including haemangiosarcoma. MicroRNAs (miRNAs) are short noncoding single-stranded RNA molecules that play a crucial role in regulating the gene expression. Some miRNAs can function as oncogenes or tumour suppressors, influencing important processes in cancer, such as angiogenesis. This study aimed to investigate whether miRNAs targeting PTEN were disrupted in canine haemangiosarcoma and its corresponding brain metastases (BM). The expression levels of miRNA-10b, miRNA-19b, miRNA-21, miRNA-141 and miRNA-494 were assessed in samples of primary canine cardiac haemangiosarcomas and their matched BM. Furthermore, the miRNA profile of the tumours was compared to samples of adjacent non-cancerous tissue and healthy control tissues. In primary cardiac haemangiosarcoma, miRNA-10b showed a significant increase in expression, while miRNA-494 and miRNA-141 exhibited downregulation. Moreover, the overexpression of miRNA-10b was retained in metastatic brain lesions. Healthy tissues demonstrated significantly different expression patterns compared to cancerous tissues. In particular, the expression of miRNA-10b was nearly undetectable in both control brain tissue and perimetastatic cerebral tissue. These findings can provide a rationale for the development of miRNA-based therapeutic strategies, aimed at selectively treating haemangiosarcoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MIDNIGHT Foundation
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Fosmire SP, Dickerson EB, Scott AM, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest. 2004;84:562-572.
Megquier K, Turner-Maier J, Swofford R, et al. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma. Mol Cancer Res. 2019;17:2410-2421.
Wang G, Wu M, Durham AC, et al. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma. PloS One. 2020;15:e0229728.
Griffin MA, Culp WTN, Rebhun RB. Canine and feline haemangiosarcoma. Vet Rec. 2021;189:e585.
Snyder JM, Lipitz L, Skorupski KA, Shofer FS, Van Winkle TJ. Secondary intracranial neoplasia in the dog: 177 cases (1986-2003). J Vet Intern Med. 2008;22:172-177.
Waters DJ, Hayden DW, Walter PA. Intracranial lesions in dogs with hemangiosarcoma. J Vet Intern Med. 1989;3:222-230.
Doolittle ND, Muldoon LL, Culp AY, Neuwelt EA. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol. 2014;71:203-243.
Kim M, Kizilbash SH, Laramy JK, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35:177.
Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5:5.
Kim JH, Graef AJ, Dickerson EB, Modiano JF. Pathobiology of hemangiosarcoma in dogs: research advances and future perspectives. Vet Sci. 2015;2:388-405.
Dickerson EB, Thomas R, Fosemire SP, et al. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol. 2005;42:618-632.
Wong S, Ehrhart EJ, Stewart S, et al. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients. PloS One. 2022;17:e0264986.
Wang G, Wu M, Maloneyhuss MA, et al. Actionable mutations in canine hemangiosarcoma. PloS One. 2017;12:e0188667.
Bartel DP. MicroRNA target recognition and regulatory functions. Cell. 2009;136:215-233.
Kane NM, Thrasher AJ, Angelini GD, Emanueli C. Concise review: microRNAs as modulators of stem cells and angiogenesis. Stem Cells. 2014;32:1059-1066.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-866.
Sun HB, Chen X, Ji H, et al. miR 494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN. Int J Oncol. 2014;45:2486-2494.
Ghafouri-Fard S, Abak A, Shoorei H, et al. Regulatory role of microRNAs on PTEN signaling. Biomed Pharmacother. 2021;133:110986.
Gao Y, Feng B, Han S, et al. The roles of MicroRNA-141 in human cancers: from diagnosis to treatment. Cell Physiol Biochem. 2016;38:427-448.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-658.
Sheedy P, Medarova Z. The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res. 2018;8:1674-1688.
Liu DT, Yao HR, Li YY, Song YY, Su MY. MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway. Oncol Lett. 2018;16:559-565.
Asproni P, Ressel L, Millanta F, Vannozzi I, Poli A. Co-localization of PTEN and E-cadherin in canine mammary hyperplasias and benign and malignant mammary tumors. Res Vet Sci. 2015;103:113-118.
Ghorbanhosseini SS, Nourbakhsh M, Zangooei M, et al. MicroRNA-494 induces breast cancer cell apoptosis and reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase expression and activity. EXCLI J. 2019;18:838-851.
Wan H, Zhang D, Hu W, et al. Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma. Medicine (Baltimore). 2021;100:e26779.
Liu K, Liu S, Zhang W, et al. miR-494 promotes cell proliferation, migration and invasion and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. Oncol Rep. 2015;34:1003-1010.
Wang J, Chen H, Liao Y, et al. Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Tumour Biol. 2015;36:6965-6972.
Shen PF, Chen XQ, Liao YC, et al. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate. 2014;74:756-767.
Song L, Liu D, Wang B, et al. miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway. Oncol Rep. 2015;34:525-531.
Li J, Wang L, Liu Z, et al. MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9. Oncotarget. 2015;6:26216-26229.
Bulkowska M, Rybicka A, Senses KM, et al. MicroRNA expression patterns in canine mammary cancer show significant differences between metastatic and non-metastatic tumours. BMC Cancer. 2017;17:728.
Joos D, Leipig-Rudolph M, Weber K. Tumour-specific microRNA expression pattern in canine intestinal T-cell-lymphomas. Vet Comp Oncol. 2020;18:502-508.
Grimes JA, Robinson KR, Bullington AM, Schmiedt JM. Identification of serum microRNAs with differential expression between dogs with splenic masses and healthy dogs with histologically normal spleens. Am J Vet Res. 2021;82:659-666.
Kim JH, Megquier K, Thomas R, et al. Genomically complex human angiosarcoma and canine hemangiosarcoma establish convergent angiogenic transcriptional programs driven by novel gene fusions. Mol Cancer Res. 2021;19(5):847-861.
Siontis BL, Zhao L, Leja M, et al. Primary cardiac sarcoma: a rare, aggressive malignancy with a high propensity for brain metastases. Sarcoma. 2019;2019:1960593.
Forterre A, Komuro H, Aminova S, Harada MA. Comprehensive review of cancer MicroRNA therapeutic delivery strategies. Cancers (Basel). 2020;12:1852.
Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene. 2010;29:937-948.
Zhang S, Cheng Z, Wang Y, Han T. The risks of miRNA therapeutics: in a drug target perspective. Drug des Devel Ther. 2021;15:721-733.
Pauli A, Rinn JL, Schier AF. Non-coding RNAs as regulators of embryogenesis. Nat Rev Genet. 2011;12(2):136-149.
Guan D, Zhang W, Zhang W, Liu GH, Belmonte JC. Switching cell fate, ncRNAs coming to play. Cell Death Dis. 2013;4(1):e464.
Großhans H, Chatterjee S. MicroRNases and the regulated degradation of mature animal mirnas. Adv Exp Med Biol. 2011;700:140-155.